Table 2 Response assessment after one cycle of induction therapy (n = 47).
N | (%) | |
|---|---|---|
ORR (CR + CRi + PR) | 42/45 | 93.3% (95% CI: 85.8–100%) |
cCR (CR + CRi) | 39/45 | 86.7% (95% CI: 76.3–97.0%) |
PR | 3/45 | 6.7% |
NR | 3/45 | 6.7% |
Not evaluated | 1/47 | 2.1% |
Died | 1/47 | 2.1% |
MRD negative (by flow cytometry) | 25/33 | 75.8% |
cCR by ELN 2022 risk group | ||
Favorable | 10/10 | 100% |
Intermediate | 4/6 | 66.7% |
Adverse | 21/25 | 84.0% |
Unknown | 4/4 | 100% |
Responders that received allo-HSCT | 4 | |
Hematological adverse events after induction, days | ||
During of WBC ≤ 1 × 109/L, days | 15 (range: 0–40) | |
During of Plt ≤30 × 109/L, days | 14 (range: 0–38) | |
Overall survival (1-year) | 66.8% (95% CI: 53.5–83.4%) | |
Even free survival (1-year) | 58.1% (95% CI: 44.4–76.0%) | |
Relapse-free survival (1-year) | 68.4% (95% CI: 54.2–86.3%) | |
